key: cord-0716357-bxgvw5q2
authors: Miller, Emily Happy; Namale, Vivian S; Kim, Carla; Dugue, Rachelle; Waldrop, Greer; Ciryam, Prajwal; Chong, Alexander M; Zucker, Jason; Miller, Eliza C; Bain, Jennifer M; Willey, Joshua Z; Doyle, Kevin; Boehme, Amelia; Claassen, Jan; Uhlemann, Anne-Catrin; Thakur, Kiran T
title: Cerebrospinal Fluid (CSF) Analysis in Patients with COVID-19
date: 2020-10-18
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa501
sha: 35b3c2624e33101f5f2a1a20e7e2e6aca651f53c
doc_id: 716357
cord_uid: bxgvw5q2

OBJECTIVE: Assessment of the impact of cerebrospinal fluid (CSF) analysis including investigation for the presence of SARS-CoV-2 is essential for the optimization of patient care. METHODS: In this case series, we review patients diagnosed with SARS-CoV-2 undergoing LP admitted to Columbia University Irving Medical Center (New York, New York) from March 1-May 26, 2020. In a subset of patients, CSF SARS-CoV-2 quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) testing is performed. RESULTS: Average age of 27 patients who undergo LP with definitive SARS-CoV-2 is 37.5 years (SD 28.7). CSF profiles show elevated WBC counts and protein in 44% and 52% of patients, respectively. LP results impact treatment decisions in 10 (37%) patients, either by change of antibiotics, influence in disposition decision, or by providing an alternative diagnosis. CSF SARS-CoV-2 qRT-PCR is performed on 8 (30%) patients with negative results in all samples. CONCLUSIONS: Among patients diagnosed with SARS-CoV-2, CSF results change treatment decisions or disposition in over one-third of our patient cohort. CSF is frequently abnormal, though CSF SARS-CoV-2 qRT-PCR is negative in all samples. Further studies are required to define whether CSF SARS-CoV-2 testing is warranted in certain clinical contexts.

The global pandemic of the novel coronavirus, SARS-CoV-2, has resulted in over 34 million cases worldwide with over one million deaths as of October, 2 2020[1]. There are growing reports of neurological symptoms and conditions seen in the context of COVID-19 including headaches, encephalopathy, seizures, cerebrovascular accidents, acute hemorrhagic necrotizing encephalopathy (AHNE), and Guillain-Barre syndrome (GBS) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . A major knowledge gap exists with regards to the frequency and mechanisms of neurological injury in COVID-19 patients. Whether these conditions are due to systemic effects of COVID-19 including multiorgan damage, coagulopathy, and systemic inflammation or whether direct viral neuroinvasion contributes remains unknown [16] .

Little is known regarding the role of lumbar puncture (LP) in COVID-19 patients with neurological symptoms. Few case reports have identified SARS-CoV-2 in the cerebrospinal fluid (CSF) by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) or sequencing techniques [14, 17, 18] . There are several recent case studies of presumed meningoencephalitis, GBS, AHNE and strokes in COVID-19 patients which have negative CSF SARS-CoV-2 qRT-PCR results [6, 10, 12, 19] . This may represent a lack of viral presence in CSF or may be impacted by factors such as timing of testing within the natural course of COVID-19 and CSF sampling techniques.

The clinical indications for performing LPs in patients with SARS-CoV-2 infection remain unclear and decisions are complicated by limitations in personal protective equipment (PPE) during hospital surges in cases, and the potential exposure of healthcare workers. Additionally, how clinicians can use information gained from LPs, such as cell counts and infectious work-up, in the management of COVID-19 and neurological symptoms has not been established. Here, we describe how results of LP influence clinical decision-making in a case series of patients with COVID-19 and M a n u s c r i p t assess whether SARS-CoV-2 is detected in the CSF by qRT-PCR in a subset of patients undergoing LP for clinical purposes.

Before initiation of data collection, the study was approved by the CUIMC Institutional Review Board. The study was approved as medical chart review and CSF collection and CSF testing for SARS CoV-2 rtPCR on CSF specimens obtained for clinical purposes, and the requirement for obtaining written informed consent was waived.

We performed a retrospective analysis of patients admitted to New York Presbyterian-Columbia Irving Medical Center (CUIMC, New York, New York) between March 1, 2020 to May 26, 2020. All patients meeting Center for Disease Control and Prevention (CDC) criteria for confirmed COVID-19 infection (i.e. patients with a positive SARS-CoV-2 RNA amplification test via nasopharyngeal swab) who underwent lumbar puncture during the same admission were included [20] . Patients were excluded if LP was therapeutic (i.e. intrathecal chemotherapy) or if LP was carried out during a different admission from nasopharyngeal (NP) SARS-CoV-2 qRT-PCR positive testing result. Demographics, clinical, and laboratory data including indication for LP and CSF results, treatment and patient outcome (alive, deceased or remains admitted) were collected through electronic medical record (EMR) review. The patient cohort included adults (>18 years of age) as well as pediatric patients. The effect of LP on clinical management was determined by clinician review of change in antimicrobials (addition or removal), ordering of additional tests, and change in disposition in direct response to LP results by review of an infectious disease physician (EHM) and neurologist (KTT). CSF samples were collected by clinical teams performing LPs for clinical purposes. For qRT-pCR testing, DNA/RNA Shield (Zymo) was added in a 1:1 ratio to CSF after collection to inactivate any A c c e p t e d M a n u s c r i p t virus, which may be present. RNA from samples was extracted using RNeasy Mini Kit (Qiagen).

Quantitative RT-PCR was performed on extracted RNA using Taqman 4X master mix and SARS-CoV-2 primer/probe sets (IDT) to detect presence of virus [21, 22] . Each assay included a standard curve to determine the viral load (log 10 copies/ml).

Patient characteristics were summarized using frequency and percent for categorical variables and mean/standard deviation or median/range for continuous variables when evaluating the characteristics of the entire population.

During the study period, 27/3598 (1%) patients admitted with COVID-19 underwent LP at our institution. The average age of patients was 37.5 years (SD 28.7), with 10 pediatric patients (70% less than 3 months of age) ( Table 1 ). 21 (78%) were male and 11 (41%) were Hispanic. Five (19%) had neurological comorbidities including prior stroke (1, 4%), epilepsy (3, 11%) and cognitive impairment (1, 4%). On admission, fever was the most common presenting symptom occurring in 13 patients (48%), followed by altered mental status (22%), headache (15%), dyspnea (7%), anosmia (6%), and psychosis occurring in 1 patient (4%). Eleven (41%) patients, including one pediatric patient, presented with predominately neurological symptoms, including altered mental status, focal motor or sensory deficits, or seizures. Six (22%) patients presented with symptoms consistent with COVID-19 including fever, cough, and/or shortness of breath. Within the pediatric patient cohort, the most common presenting symptom was fever (8, 80%). Screening COVID-19 testing was done on all patients being admitted to the hospital at this time, regardless of presenting symptoms.

LPs were performed due to clinical concern for CNS infection given clinical symptoms of altered mental status (5,19%) , clinical symptoms or signs of meningitis or encephalitis (6, 22%) and seizures/status epilepticus (3,11%). The remaining 13 patients had LPs performed for a variety of indications including EVD placement/concern for ventriculitis (3, 11%), other neurological symptoms such as transverse myelitis and flaccid quadriplegia (3, 11%), fevers in neonates or young children (6, A c c e p t e d M a n u s c r i p t 22%), and multisystem inflammatory syndrome in children (1, 4%) (Table 1) . In adult patients, the average duration of symptoms (neurological and/or systemic) prior to LP being performed was 11.5 days (2 days, >30 days). In the adult cohort, duration of symptoms prior to presentation could not be obtained for 3 patients due to altered mental status at time of presentation with no documentation of collateral history. Five adult patients had greater than 30 days between reported onset of symptoms and LP as 4 (22%) patients initially presented with predominately COVID-19 related respiratory symptoms. For all patients included in the study, the average time from last positive NP swab for SARS-CoV-2 to LP was 8 days (0, 38 days). In the majority of pediatric patients (8, 80%) who presented with fevers, LP was performed on the same day as positive SARS-CoV-2 test and on the same day as symptom onset.

Neuroimaging was performed in 18 cases (67%) with 5 cases (27%) notable for acute or subacute ischemic strokes (1 with hemorrhagic conversion), 6 (33%) with intracranial hemorrhages, 2 (11%) for microhemorrhages, 1 (6%) with evidence of kinking of the orbital nerves, 2 (11%) with evidence of focal parenchymal FLAIR/T2 hyperintensities, 2 (11%) with dural enhancement, and 1 (6%) with leptomeningeal enhancement (Figure 1 , Supplemental Table 1 ). Continuous EEG was performed in 14 (52%) patients with diffuse slowing recorded in 11 (79%), focal slowing in 1 (7%) and 2 (14%) had evidence of electrographic seizures.

One patient who presented with occipital headache and fever was positive on the Biofire meningitis-encephalitis (ME) PCR panel for Streptococcus pneumoniae ( Table 2 ) as well as for COVID-19 on NP swab [23] . Ten patients (37%) had bloody CSF samples with >1000 RBC/mm3, including 4 patients found to have intracranial hemorrhages with CSF from three of the patients drawn from external ventricular devices (EVDs). An elevated CSF white blood cell (WBC) count greater than In this case series a subset of patients had CSF tested for the presence of SARS-CoV-2 by qRT-PCR, and all samples tested were negative for the virus. This is consistent with recent case series which included CSF testing for SARS-CoV-2 by qPCR where samples have also largely tested negative [18, 24, 25] . Combined, these results suggest that SARS-CoV-2 is unlikely to be present in CSF in the majority of patients. However, several factors may have precluded detection of the virus in CSF. First, the duration of viral illness prior to LP may be a factor. Prior studies have shown that in the respiratory tract viral levels are highest in the first week of infection [26] . If virus is present in the CSF, it may be present very early on in the disease when viral loads are highest, and therefore timing of the LP would be essential to detect virus in the CSF. In the case series from Neumann et al, the average time from positive nasopharyngeal SARS-CoV-2 test to LP was 5.9 days (+/-9.8 days) [18] . In this case series, three patients had an LP performed within 5 days of their A c c e p t e d M a n u s c r i p t reported onset of symptoms, but the remaining patients tested had a longer time period between reported symptom onset and LP. CSF samples may have been falsely negative for SARS-CoV-2 due to extended periods of time between onset of symptoms and performance of LP, as the viral kinetics in CSF is currently unknown and requires further study.

Presenting symptoms in many cases are not classical COVID-19 related symptoms (i.e fever, cough, dyspnea), with many adult patients presenting with neurological symptoms such as weakness. Some patients had symptoms which could overlap with both COVID-19 and a primary neurological condition such as headache and fever. Additionally, several patients presented with altered mental status, making it difficult to determine how long symptoms had been present prior to presentation. Many of these patients had predominately neurological rather than respiratory symptoms at time of LP, raising the concern for possible COVID-19 related neurological disease or that neurological symptoms may mask more typical symptoms of COVID-19. In these patients, CSF profiles were abnormal in a majority, however the role of LP in the diagnosis of potential COVID-19 related CNS disease remains unclear.

Other factors which could have contributed to the negative CSF findings may be related to the test itself. Degradation of viral particles and RNA prior to qRT-PCR testing could be a factor. CSF for this study was placed in DNA/RNA stabilizing buffer, to preserve any viral RNA present, but time from sample collection to addition of stabilizing buffer varied case to case. While qRT-PCR is a validated and widely used test for detection of virus in respiratory samples, the use in CSF samples is less well defined. It is possible that an alternative test, such as SARS-CoV-2 antibody testing in the CSF may be a better test of prior viral presence in the CSF though this remains to be defined. At the time of the study, we did not have the ability to perform CSF antibody testing. Absence of virus in the CSF does not rule out neurotropism of the virus. Recent neuropathological studies of COVID-19 patients A c c e p t e d M a n u s c r i p t have identified viral RNA by qRT-PCR in the brain though inconsistently, and typically with low viral loads of uncertain clinical significance when reported [27] [28] [29] .

While SARS-CoV-2 was not detected in CSF samples by qRT-PCR in our small cohort, many patients included in this study had abnormal CSF profiles. In the majority of adult cases, the infectious work-up done on the CSF (bacterial gram stain and culture, Biofire ME panel, and other CSF studies) were negative. In these cases, the inflammatory nature of the CSF profile is of particular interest. A significant number of patients here had ischemic strokes or ICHs with history or radiographic pattern concerning for possible CNS infection by neurology teams involved. Patients presenting with ischemic or hemorrhagic stroke typically have LPs if there is radiographic or clinical concern for vasculitis/vasculopathy, or the patient is immunocompromised [30] . Though data is limited, in patients with ischemic strokes, the CSF WBC count can be mildly elevated in the first week with elevated protein, though rarely above 100 mg/dl, in about half of cases [30] . In patients with ICH, CSF profiles can vary significantly, and can show a neutrophilic pleocytosis and highly elevated protein, up to 2000 mg/dL, based on limited data [30] . Three patients in this case series had EVDs placed for ICH. Collection of CSF from EVDs may lead to an elevated WBC in CSF and may have accounted for some of the observed increases.

A subset of patients with COVID-19 go on to develop a systemic hyperinflammation syndrome [31] . It is possible that the inflammatory profile of the CSF seen in some of these Given the broad spectrum on neurological findings described in this case series, the question of when to obtain an LP in COVID-19 patients remains important. Prior recommendations suggest LPs be performed in COVID-19 patients where there is concern for encephalitis or neurological findings such as new deficits, CVAs, seizures or delirium which is not able to be explained by other causes, but indications for LP in COVID-19 patients remains challenging [32] . Our data does not support the routine testing of CSF for the presence of SARS-CoV-2, however this case series shows M a n u s c r i p t 

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neurologic Features in Severe SARS-CoV-2 Infection

Characteristics of ischaemic stroke associated with COVID-19

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Coexistence of COVID-19 and acute ischemic stroke report of four cases

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?

Guillain Barre syndrome associated with COVID-19 infection: A case report

Guillain-Barré syndrome related to COVID-19 infection

Guillain-Barré syndrome following COVID-19: new infection, old complication

Miller Fisher Syndrome and polyneuritis cranialis in COVID-19

Neurologic manifestations in an infant with COVID-19

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features

COVID -19: A Global Threat to the Nervous System

Sars-Cov-2: Underestimated damage to nervous system

Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms

Steroid-Responsive Encephalitis in Coronavirus Disease

COVID-19) 2020 Interim Case Definition

US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2

Control CfD. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT PCR Diagnostic Panel

FilmArray meningitis/encephalitis (ME) CE-IVD Instruction For Use

Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic. The Lancet Microbe

Validation of SARS-CoV-2 detection across multiple specimen types

Temporal dynamics in viral shedding and transmissibility of COVID-19

Neuropathological Features of Covid-19

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Multiorgan and Renal Tropism of SARS-CoV-2

Cerebrospinal Fluid in Diseases of the Nervous System

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t